In a commentary published in the American Journal of Managed Care, IVI's Jennifer Bright, EveryLife Foundation's Annie Kennedy, and National Health Council's Eleanor Perfetto teamed up to describe how their organizations are joining forces to advance patient-centric value assessment measurements. "Patient centricity" — engaging with patients as partners, rather than doing on behalf of the [...]
With attention increasingly focused on the Biden Administration's new interest in a German-style panel to determine fair healthcare pricing, Jennifer Bright says we're at a crucial time to be absolutely clear about value - and how to measure it with patients' perspectives fully represented. Read about IVI's principles for HTA in the US on the [...]
IVI and the University of Maryland Pharmacy School’s PAVE Center Partner on Patient-Centered Value Assessment
In an article in The Patient, IVI and the Patient-Driven Values in Healthcare Evaluation (PAVE) Center at the University of Maryland School of Pharmacy describe how they develop methods and models that make patient-centered value assessment both scientifically feasible and relevant to real-world decisions across the range of stakeholders. Read the full article here.
In a commentary in AJMC, IVI examines how multi-criteria decision analysis has the potential to better understand and assess value for innovative cell and gene therapies which are transforming the lives of patients living with serious diseases. Read the full article here.
IVI's Jennifer Bright and Mike Thompson of the National Alliance for Healthcare Purchasers share how employers can use depression as a "test case" for thinking about how to improve the value assessment process, so that we can apply a "purchaser-patient" lens up front. Read the full article on Employers Benefit News here.
Value assessment is a hot topic in healthcare. But how can it be improved so it's more relevant to answering the most important questions to patients, payers and providers? In this commentary, Jennifer Bright explains why we need data partners to catalyze improvement in value assessment. Read the article here.
Jennifer Bright discusses the following three trends that began in 2019 and will pick up steam this year: Increased demand for value information for drugs; Increased number of voices asking whether value assessment is done the right way; and Momentum to improve value assessment models. Read the full article here. Please note that a Scrip [...]
Jennifer Bright writes in Morning Consult that while we've made progress assessing the value of biopharmaceuticals, more focus is needed to develop bout transparent, patient-centered value assessment methods in healthcare technologies beyond drugs. Read the full article here.
IVI offered comments on ICER's recently released Draft Evidence Report examining the cost-effectiveness of Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis. In addition to commenting on the needs for transparency and the impacts of modeling assumptions on results, IVI's comments raise a broader question about the relevance of the analysis to decision making. IVI writes [...]
Jennifer Bright writes in Benefits Pro that employers who rely on health plans and vendors to advise them on coverage for drugs or other treatments need to ask several key questions to ensure they are getting the most value out of their consultants' recommendations. Read the full article here.